Innovative Green Product Synthesis and Renewable Environment Development Research Group, Faculty of Environment and Labour Safety, Ton Duc Thang University, Ho Chi Minh City, Viet Nam.
School of Chemical Engineering, Yeungnam University, Gyeongsan, Gyeongbuk 38541, Republic of Korea.
Int J Pharm. 2018 Mar 25;539(1-2):104-111. doi: 10.1016/j.ijpharm.2018.01.034. Epub 2018 Jan 31.
Cancer is an abnormal condition leading to uncontrolled cell division which causes damage to the body tissues. Around 100 types of cancer are studied so far namely breast cancer, lung cancer, skin cancer, prostate cancer, colon cancer and lymphoma. Major cancer therapies include chemotherapy, surgery and radiations but their major drawbacks are non-specifically distributed antitumor agents, uneven delivery of drug concentration to the tumour and low monitoring. Nanoparticles (NPs) are the newly trending field of nanomedicine implied in cancer therapy. The structural characteristics of NPs makes them excellent mode for targeting and penetrating the abnormal cell growth caused by cancer. They can potentially enter the abnormal cells causing DNA damage and determine the defects in the genes. Apart from targeting cancer cells they also aid in drug delivery, imaging of abnormal cells, release and monitoring of therapeutic agents against cancer. The present review deals with the inorganic NPs mediated pharmacotherapy, potential strategies for developing drug delivery system, evaluate the merits and demerits of traditional chemotherapy and nanotherapy for significantly improving the treatment of cancers.
癌症是一种导致不受控制的细胞分裂的异常情况,从而对身体组织造成损害。迄今为止,已经研究了大约 100 种癌症,包括乳腺癌、肺癌、皮肤癌、前列腺癌、结肠癌和淋巴瘤。主要的癌症疗法包括化疗、手术和放疗,但它们的主要缺点是抗肿瘤药物分布不均匀、药物浓度不均匀地输送到肿瘤部位以及监测效果不佳。纳米颗粒(NPs)是纳米医学领域的新兴趋势,应用于癌症治疗。NPs 的结构特征使其成为靶向和穿透由癌症引起的异常细胞生长的理想模式。它们可以潜在地进入异常细胞,导致 DNA 损伤,并确定基因缺陷。除了靶向癌细胞外,它们还有助于药物输送、异常细胞成像、释放和监测针对癌症的治疗剂。本综述涉及无机 NPs 介导的药物治疗,开发药物输送系统的潜在策略,评估传统化疗和纳米治疗的优缺点,以显著改善癌症的治疗效果。
Int J Pharm. 2018-1-31
Eur J Pharm Biopharm. 2015-6
Annu Rev Pharmacol Toxicol. 2015-10-28
Drug Resist Updat. 2011-2-16
Crit Rev Eukaryot Gene Expr. 2018
Anticancer Drugs. 2011-11
Nanomedicine (Lond). 2007-10
J Control Release. 2016-10-26
J Nanosci Nanotechnol. 2018-8-1
Exp Hematol Oncol. 2025-5-19
Exp Hematol Oncol. 2025-4-30
Theranostics. 2025-1-1
Naunyn Schmiedebergs Arch Pharmacol. 2025-5
Cancers (Basel). 2024-10-24